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Bacteriophages:
 The Answer to 
Antibiotic Resistance?
Bacteriophages, viruses that infect bacteria, have numerous applications in the medical, agricultural, and 
research fields, especially as an alternative to antibiotics in the age of antibiotic resistance. Phages are able 
to lyse, or break apart, bacterial cells with fewer side effects, more specificity, and less likelihood of resistance 
than antibiotics. The acceptance of phages in medicine and agriculture around the world today is not 
universal, and the United States Food and Drug Administration (FDA) has been slow to recognize phage 
therapy as a legitimate treatment. However, the successful use of phages in the past, as well as promising 
trial results in fields ranging from chronic disease treatment to food preservation, present opportunities for 
consideration of phage-based applications in the future. The goal of this paper is to provide an overview of 
the history, uses, and regulation of phage therapy.
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communication between Eastern Europe and the Western 
world during World War II and the counterintuitive nature 
of using viruses to treat diseases (Summers, 2012). In 
addition, the difficulty in regulating a virus as a therapeutic 
agent is still a major barrier.
During World War II, the Allied and Axis powers differed 
in regard to method of treatment for bacterial infections. 
While German scientists studied phages, the Allies were 
heavily dependent on antimicrobial drugs like penicillin 
and amoxicillin (Summers, 2012). The efficacy and speed 
of these pharmaceuticals were a major breakthrough in 
the medical industry, surpassing the still-developing phage 
therapy. Antimicrobial drugs were produced in great 
quantities, rendering phage therapy virtually obsolete. 
Recently, the emergence of bacterial resistance to antibiotics 
has caused researchers to seek alternative methods of 
treatment (Yosef, Kiro, Molshanski-Mor, Edgar, & Qimron, 
2014).
Although ignored for several decades in the West, the 
decline of phage therapy was neither uniform nor complete, 
as evidenced by its continued use in the Republic of Georgia 
by the Tbilisi Institute (Kutateladze & Adamia, 2008). No 
substantial research or well-documented practice of phage 
therapy arose for the next 40 years; however, in the last 
few decades phage therapy research has reemerged in the 
Western world to combat the urgent problem of antibiotic 
resistance.
Current Uses and Future Applications of 
Phages
While many phage treatments are not yet supported by 
the United States’ Food and Drug Administration (FDA), 
research has shown phages to be beneficial in areas like 
food preservation, agriculture, livestock health, and the 
treatment of human infections. Several uses that will 
be discussed include overcoming antibiotic resistance, 
sterilizing medical equipment, and treating agricultural 
products. 
A promising technique for overcoming antibiotic resistance 
involves using specific proteins from phages that lyse 
bacteria, and can be isolated and used to treat bacterial 
infections. Phage therapy significantly increases the 
ability to combat antibiotic resistance in bacteria such as 
Staphylococcus aureus, Pseudomonas aeruginosa, Klebsiella 
pneumoniae, and Escherichia coli with 90% efficiency (Pirisi, 
2000). These bacteria are known to cause a variety of health 
problems like staph infections, pneumonia, bronchitis, 
meningitis, and gastroenteritis, respectively. Additionally, 
phages are effective against ten of the most antibiotic-
resistant strains of E. coli (Rahmani, Zarrini, Sheikhzadeh, 
& Aghamohammadzadeh, 2014). Table 1 shows several 
comparisons between bacteriophages and antibiotics and 
offers a condensed view of phage therapy viability. The 
Introduction
If you were to walk out into your backyard today, 
you probably wouldn’t notice the thousands of tiny 
microorganisms living there right underneath your feet. 
Many of these microorganisms would be bacteria, but 
at least ten times as many would be their viral predators 
(Hattful, 2008). These bacteria-infecting viruses, called 
bacteriophages or “bacterium-eaters,” were discovered in 
1910 by Felix d’Herelle, a French-Canadian microbiologist 
(Golkar, Bagasra, & Pace, 2014). One example of a 
bacteriophage is shown in Figure 1. They can be found 
almost anywhere on Earth and are a topic of increasing 
study, especially due to the dramatic rise of antibiotic 
resistance. Bacteriophage research is conducted worldwide 
in an effort to combat this resistance and address a variety 
of health issues, ranging from chronic diseases to safety in 
the food industry.
Figure 1. An electron micrograph image of a siphovirus 
isolated by Isabel Jimenez-Bush from a soil sample in a JMU 
Viral Discovery class. Note the icosahedral head along with 
the long flexible tail.
History of Phage Therapy
The use of bacteriophages to treat pathological bacterial 
infections, called phage therapy, began in France in 1919. 
By the 1930s, phage therapy was in use in Europe and the 
United States (Highfield, 2014). After the introduction 
of antibiotics, however, phage therapy became virtually 
obsolete everywhere except Eastern Europe and the 
Soviet Union. The decline in phage therapy was the result 
of multiple factors, including the cessation of research 
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use of phages as antibacterial agents in the past century in 
other places than the United States has had a lasting impact 
on the treatment of bacterial infections (Abedon, Kuhl, 
Blasdel, & Kutter, 2011).
Regulating Applications of Phage Therapy
The policy decisions regarding characterization of phages 
as medicinal products are controversial due to the varying 
definitions of bacteriophages and efficacy of phage therapy. 
In many countries, phage therapy is placed into one or 
more of three categories: a general medicinal product, 
a biological medicinal product (such as a vaccine), or an 
advanced medicinal product (such as gene therapy). In 
Europe, phage therapy is already implemented and is 
considered a biological and medicinal product suitable 
for human use (Verbeken et al., 2014). The European 
Regulatory Framework dictates that phage therapy should 
be delivered through a mixture of bacteria-specific phages 
also known as “phage cocktails.” For non-life-threatening 
infections, these cocktails are sold over the counter. Phage 
cocktails that target potentially life-threatening bacterial 
infections, however, are only administered in a hospital 
setting (Verbeken et al., 2014).
Phage Cocktail Therapy has yet to be fully supported by 
the FDA for direct treatment of human disease because 
each phage must be approved individually (Keen, 2012). 
An example of the FDA’s hesitation toward this type of 
therapy is the production of Staphylococcal Phage Lysate 
(SPL) in 1959. SPL can be used to treat wounds infected 
with Staphylococcus aureus and after safety trials were 
conducted, SPL was licensed for administration in human 
treatment. However, the production of SPL for human 
treatment was suspended in the 1990s due to regulatory 
pressure from government agencies. Currently, SPL is 
approved and utilized only for veterinary applications 
(Golkar et al., 2014). 
In regard to the food industry, in 2006 the FDA approved 
phage food additives to combat contamination, particularly 
for anti-Listeria treatment (“Food Safety,” 2015). Phages 
can be used to treat Listeria in ready-to-eat meat, and 
bacterial damage of tomatoes and peppers, and treatments 
are recognized as compatible with organic food production. 
Additionally, the FDA has approved phage use in treatment 
of bacterial pathogens such as E. coli, Salmonella, and 
Campylobacter (Golkar et al., 2014).
Phage Therapy and Campylobacter jejuni. 
The use of phages in the food industry includes the 
treatment of the Campylobacter jejuni bacterium. The 
Campylobacter jejuni bacterium is the most common cause 
of gastroenteritis in humans. Commonly found in the feces 
and intestinal tracts of poultry, the C. jejuni bacterium 
causes contamination of poultry meat. One method of 
preventing infection involves dosing live poultry with 
bacteriophage cocktails to lessen the amounts of C. jejuni 
in their intestinal tracts (Hammerl et al., 2014).
Hammerl et al. (2014), studied the effects of the introduction 
of the Myoviridae bacteriophage family on the C. jejuni 
bacterium found in broiler chickens. In this study, some 
chickens were treated with single phages and others with 
groups of phages (Hammerl et al., 2014). The phages were 
Side Effects Targeting Ability
Site 
Specificity Resistance
Treatment 
Development
Bacteriophages No serious 
known side 
effects
Infect targeted 
pathogenic 
bacteria
Congregate at 
infection site
Rarely encounter 
phage-resistant 
bacteria which 
are typically 
susceptible to other 
phages
Can easily select 
specific phages 
to develop new 
treatments 
quickly; new 
phage treatments 
are easy to 
develop due to 
high specificity of 
phages
Antibiotics Can cause side 
effects such 
as allergies, 
intestinal 
disorders, and 
secondary 
infections
Target both 
pathogenic 
microorganisms 
and normal 
microflora, which 
affects microbial 
balance in patients
Do not 
concentrate at 
the infection 
site and are 
eliminated 
from the body 
over time
Antibiotic-
resistant bacteria 
are common and 
develop from non-
selected bacteria 
during antibiotic 
treatment
New antibiotics 
are developed 
slowly
Table 1. Comparing and Contrasting Bacteriophages and Antibiotics
Note. Chart adapted from “Bacteriophage Therapy,” by A. Sulakvelidze, Z. Alavidze, and J. G. Morris, 2001, Antimicrobial Agents  
and Chemotherapy, 45(3), 649–659.
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of disease-causing phages could allow for development of 
new and effective treatments.
Phage Application in Cleaning Surfaces
Another environment prone to resistant bacteria is hospital 
equipment. Bacterial colonies growing on the surfaces 
of hospital equipment often come into contact with 
antibacterial cleaning supplies. This common interaction 
allows the bacteria to develop resistance to these cleaners. 
Research is being conducted to devise a technique to 
clean hospital surfaces while treating resistant bacteria 
using bacteriophages (Viertel, Ritter, & Horz, 2014). These 
cleaners prove less of a hurdle for regulation due to the fact 
that they would not be used directly on humans.
Susceptibility in Antibiotic-Resistant Bacteria
Another technique to combat antibiotic resistance is to use 
phages that insert their genome into the host bacterium to 
transfer susceptibility genes back into the bacterial genome 
(Viertel et al., 2014). This allows bacteria that were once 
antibiotic resistant to regain susceptibility to antibiotics. 
This occurs because the genes that 
are transferred into the bacterium 
increase the permeability of its cell 
membrane and allow medications 
to pass through it more freely. 
Therefore, doctors will be able to 
use antibiotics that they are familiar 
with, an approach that is more 
likely to be accepted by the FDA (Viertel et al., 2014).
Endolysins
Endolysins are phage-produced enzymes that rupture a 
bacterial host cell. These endolysins are specific proteins 
with known structures that can be defined and therefore 
regulated. The controversies surrounding use of whole 
phages or mixtures of phages, including their chemical 
and biological classification, may ultimately inhibit the 
approval of phage therapy in the U.S. However, endolysins 
may provide a solution. As endolysins are static chemicals 
similar to antibiotics, they may prove more successful in 
regulation and approval by the FDA. 
In addition, endolysins are only required in small doses 
(Ghannad & Mohammadi, 2012). Researchers at Seoul 
National University in South Korea studied the use of 
a phage called PCB1 against Bacillus cereus, a bacterium 
known to cause food poisoning in humans. PCB1 itself was 
only able to successfully infect 1 out of 22 B. cereus strains; 
however, the purified endolysins produced by the phage 
were able to successfully lyse all strains of Bacillus bacteria 
(Kong & Ryu, 2015). The lytic activity of the endolysin 
suggests that these chemicals not only appear to be more 
favorable due to their static nature, but also may have 
broader and more successful applications against bacteria 
than phages themselves
categorized into three groups based on genome size and 
morphology. Phages in group II were able to infect more 
strains of bacteria than group III, though some of the 
phages in group III had a higher lytic activity, meaning they 
were more effective at killing the bacteria of the strains that 
they were able to infect. After comparing the ability of these 
phage groups to reduce C. jejuni numbers, the researchers 
found that the chickens treated with a combination of 
phages from groups II and III had the greatest reduction 
of C. jejuni in their intestinal tracts (Hammerl et al., 2014). 
The results of this study could positively impact the future 
of food safety.
Phage Therapy and Pseudomonas aeruginosa. 
Pseudomonas aeruginosa is an opportunistic, multidrug-
resistant bacterium commonly found among the human 
microbial flora of the skin. However, if this seemingly 
harmless bacterium is introduced into the bloodstream, 
it can cause serious complications, including sepsis, an 
often fatal bacterial infection of the blood (Vieira et al., 
2012). Vieira et al. (2012) demonstrated in their study 
that immediately after phages were 
applied to infected human skin 
the amount of resistant bacteria 
significantly decreased from a 
control of 106 CFU (colony forming 
units) per square centimeter to 
102 CFU per square centimeter. 
This nearly ten billion CFU per 
square centimeter drop supports the effectiveness of phage 
therapy. In addition, the experiment exhibited that only 
one application of phages was necessary as subsequent 
applications did not lower the bacterial concentration. This 
proves promising for treating multidrug-resistant bacterial 
infections using phage therapy (Vieira et al., 2012).
Potential Use of Phages in Treatment of Crohn’s Disease
Another use of phage therapy in medical research can be 
seen through the treatment of Crohn’s disease (CD). CD is 
commonly called regional enteritis, or inflammatory bowel 
disease, and its cause is unknown. Josef Wagner, researcher 
at Murdoch Children’s Research Institute, has investigated 
the differences in the bacteriophages present within the 
gut and small intestine of pediatric patients that have CD 
(Wagner et al., 2013). The researchers analyzed the genome 
of the phages to determine if these phages were unique 
to the intestines. Ultimately, they found that CD patients 
exhibited a higher amount of unique bacteriophages 
compared to their control counterparts. Overall, the large 
abundance of phage composition within CD ileum tissue 
and CD gut wash samples suggests a role of phages in CD 
development. Researchers assumed that the increase in 
the amount of phages indicated that the bacterial count 
was higher. Therefore, the presence of specific phages may 
coincide with specific bacterial counterparts (Wagner et al., 
2013). Because phages are host-specific, the identification 
The identification of 
disease-causing phages could 
allow for development of 
new and effective treatments.
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Combination Therapy
The most successful phage therapy is the combined usage 
of bacteriophages and antibiotics. By using this technique, 
treatment has shown a promising increase in the reduction 
of bacterial infection and reducing the amount of bacteria 
evolving to develop antibiotic resistance. In the future, 
using both bacteriophages and antibiotics to fight infections 
may appease drug companies that seek the opportunity 
to continue producing their own medications, while 
increasing the effectiveness of phage therapy treatment 
(Viertel et al., 2014).
Conclusion
Phage therapy presents numerous advantages and options 
for medical research and scientific application. It is not 
currently in use in the United States due to a lack of 
regulatory ability and a large-scale control study, as well as 
the controversies surrounding the use of phages. New routes 
of regulation and classification will have to be established 
for phages to enter mainstream use in the U.S. Phages 
are being studied with broader host ranges, and being 
tested on their ability to kill pathogenic bacteria without 
harming the patients or destroying the body’s natural 
flora. Other areas of phage research include sterilization 
techniques for hospital equipment, endolysin usage that 
may surpass phage usage alone, and combination of phage 
and antibiotic therapies that could potentially result in 
approval for future use of phages. Phage research has 
also shown promising results in reintroducing antibiotic 
susceptibility into antibiotic resistant bacteria, which has 
become an increasingly prevalent issue in the modern 
medical world. In addition to combatting antibiotic 
resistance, phage therapy could eventually be used as a 
more effective alternative for bacterial infections. For these 
reasons, phages are a promising medical and industrial tool 
worldwide in the future.
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